Vir Biotechnology, Inc. - 8-K Filing
Vir Biotechnology reports Phase 3 ECLIPSE 1 trial meeting primary endpoint with 44% response rate in chronic hepatitis delta patients. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events)
Tickers: $VIR
Read the full article at SEC EDGAR
Part of the story Vir Biotechnology Reports Positive Phase 3 Trial Results for Chronic Hepatitis Delta Treatment (4 articles)